Published in PLoS Pathog on November 20, 2009
A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol (2010) 0.96
Innate immunity in acute HIV-1 infection. Curr Opin HIV AIDS (2011) 0.95
Myeloid dendritic cells in HIV-1 infection. Curr Opin HIV AIDS (2011) 0.86
Plasmacytoid dendritic cell dynamics tune interferon-alfa production in SIV-infected cynomolgus macaques. PLoS Pathog (2014) 0.85
Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients. J Virol (2010) 0.84
Dissecting the role of dendritic cells in simian immunodeficiency virus infection and AIDS. Immunol Res (2011) 0.83
HIV-1 and HIV-2 differentially mature plasmacytoid dendritic cells into IFN-producing cells or APCs. J Immunol (2014) 0.79
Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle? Virology (Auckl) (2013) 0.79
Simian immunodeficiency virus interactions with macaque dendritic cells. Adv Exp Med Biol (2013) 0.77
Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. J Clin Cell Immunol (2014) 0.77
Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness. Hum Vaccin Immunother (2013) 0.77
IFN-α-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment. J Interferon Cytokine Res (2015) 0.75
Pathophysiology of CD4+ T-Cell Depletion in HIV-1 and HIV-2 Infections. Front Immunol (2017) 0.75
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol (2005) 8.33
Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol (2008) 6.17
CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med (2002) 5.18
Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest (2005) 5.00
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med (2008) 4.55
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med (2009) 4.22
Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med (2006) 4.17
Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (1993) 3.91
CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol (2002) 3.85
Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science (1989) 3.43
Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science (1994) 3.10
Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood (2001) 3.00
Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol (2008) 2.59
HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood (2006) 2.58
Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood (2001) 2.57
Antigen-presentation properties of plasmacytoid dendritic cells. Immunity (2008) 2.57
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol (2004) 2.48
Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med (1987) 2.32
HIV-1 immunopathogenesis: how good interferon turns bad. Clin Immunol (2006) 2.23
Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin Immunol (2001) 2.19
Elite control of HIV Infection: implications for vaccines and treatment. Top HIV Med (2007) 2.16
Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood (2001) 2.16
Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci U S A (2006) 2.08
Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis (2002) 2.08
HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest (2008) 2.06
HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A (2007) 2.01
Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood (2008) 1.99
Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J Virol (2005) 1.97
Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus. J Virol (2001) 1.92
Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis (1999) 1.89
Parallel loss of myeloid and plasmacytoid dendritic cells from blood and lymphoid tissue in simian AIDS. J Immunol (2007) 1.86
Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol (2007) 1.77
Cellular and plasma viral load in patients infected with HIV-2. AIDS (1993) 1.76
Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS (2002) 1.67
HIV-2: the forgotten AIDS virus. Trends Microbiol (2008) 1.66
Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS Pathog (2009) 1.66
Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome. J Virol (2008) 1.62
HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One (2008) 1.61
Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol (1999) 1.54
Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis (2005) 1.54
Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J Virol (2000) 1.46
Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS One (2007) 1.45
Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.40
Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS (2008) 1.39
Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy. J Clin Immunol (2004) 1.38
Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med (2000) 1.37
Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. J Virol (2008) 1.36
9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet (1997) 1.35
Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon. Proc Natl Acad Sci U S A (1989) 1.35
Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol (2000) 1.32
Interferons in the persistence, pathogenesis, and treatment of HIV infection. AIDS Res Hum Retroviruses (1992) 1.26
Lessons from the second AIDS virus, HIV-2. AIDS (1996) 1.24
HIV type 2 proviral load measured by quantitative polymerase chain reaction correlates with CD4+ lymphopenia in HIV type 2-infected individuals. AIDS Res Hum Retroviruses (1994) 1.24
Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression. Blood (2009) 1.24
Variations in plasmacytoid dendritic cell (PDC) and myeloid dendritic cell (MDC) levels in HIV-infected subjects on and off antiretroviral therapy. J Clin Immunol (2006) 1.23
The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol (1990) 1.18
Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? Nat Immunol (2007) 1.17
Interferon-regulated Mx genes are not responsive to interleukin-1, tumor necrosis factor, and other cytokines. J Virol (1991) 1.17
Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment. AIDS (2006) 1.16
Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients. J Acquir Immune Defic Syndr (2008) 1.15
Type I interferon-dependent gene MxA in perinatal HIV-infected patients under antiretroviral therapy as marker for therapy failure and blood plasmacytoid dendritic cells depletion. J Transl Med (2008) 1.11
Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology (1993) 1.11
Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression. Blood (2009) 1.10
Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS (2008) 1.07
Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal. J Virol (2004) 1.06
Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J Virol (2000) 1.04
Comparison of the frequency of interleukin (IL)-2-, interferon-gamma-, and IL-4-producing T cells in 2 diseases, human immunodeficiency virus types 1 and 2, with distinct clinical outcomes. J Infect Dis (2001) 1.03
HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype. Proc Natl Acad Sci U S A (2008) 0.98
Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology (2007) 0.98
Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection. J Virol (2006) 0.94
Marked immunosuppressive effects of the HIV-2 envelope protein in spite of the lower HIV-2 pathogenicity. AIDS (2000) 0.92
Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. J Virol (2007) 0.92
Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assay. J Clin Microbiol (1999) 0.90
The production of beta-chemokines induced by HIV-2 envelope glycoprotein. AIDS (1997) 0.87
Monocyte-mediated T cell suppression by HIV-2 envelope proteins. Eur J Immunol (2007) 0.83
Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections. Cytokine (2009) 0.82
Human immunodeficiency virus type 2 envelope glycoprotein binds to CD8 as well as to CD4 molecules on human T cells. J Virol (1997) 0.82
Proviral load and immune function in blood and lymph node during HIV-1 and HIV-2 infection. Clin Exp Immunol (1999) 0.80
Dendritic cell differentiation and maturation in the presence of HIV type 2 envelope. AIDS Res Hum Retroviruses (2009) 0.78
Increased frequency of CD25dimCD4+ T-cells in HIV-2 infection, a naturally occurring attenuated form of HIV-1. Clin Immunol (2008) 0.77
CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med (2002) 5.18
CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol (2002) 3.85
Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS (2005) 1.41
Thymocyte emigration is mediated by active movement away from stroma-derived factors. J Clin Invest (2002) 1.20
IL-7 sustains CD31 expression in human naive CD4+ T cells and preferentially expands the CD31+ subset in a PI3K-dependent manner. Blood (2008) 1.17
Primary B-cell deficiencies reveal a link between human IL-17-producing CD4 T-cell homeostasis and B-cell differentiation. PLoS One (2011) 1.02
Recent thymic emigrants are the preferential precursors of regulatory T cells differentiated in the periphery. Proc Natl Acad Sci U S A (2013) 1.00
Multiple aseptic liver abscesses as the initial manifestation of Crohn's disease: report of a case. Dis Colon Rectum (2009) 0.99
Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir Ther (2006) 0.97
Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection. J Virol (2006) 0.94
First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID): a report of 2 cases. Blood (2010) 0.94
The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients. Retrovirology (2008) 0.93
Rate of increase in circulating IL-7 and loss of IL-7Ralpha expression differ in HIV-1 and HIV-2 infections: two lymphopenic diseases with similar hyperimmune activation but distinct outcomes. J Immunol (2007) 0.89
Molecular epidemiological analysis of paired pol/env sequences from Portuguese HIV type 1 patients. AIDS Res Hum Retroviruses (2011) 0.89
Heterologous cells cooperate to augment stem cell migration, homing, and engraftment. Blood (2002) 0.89
Human γδ thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2/IL-15 signaling. J Immunol (2014) 0.88
PD-1 and its ligand PD-L1 are progressively up-regulated on CD4 and CD8 T-cells in HIV-2 infection irrespective of the presence of viremia. AIDS (2012) 0.88
Origin and epidemiological history of HIV-1 CRF14_BG. PLoS One (2011) 0.87
Human FOXN1-deficiency is associated with αβ double-negative and FoxP3+ T-cell expansions that are distinctly modulated upon thymic transplantation. PLoS One (2012) 0.87
Cerebellar atrophy in systemic sclerosis. J R Soc Med (2004) 0.86
Brachiocephalic vein thrombosis associated with Crohn's disease. J Gastroenterol (2003) 0.86
Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients. J Virol (2010) 0.84
Differentiation of human thymic regulatory T cells at the double positive stage. Eur J Immunol (2011) 0.84
Monocyte-mediated T cell suppression by HIV-2 envelope proteins. Eur J Immunol (2007) 0.83
TACI deficiency enhances antibody avidity and clearance of an intestinal pathogen. J Clin Invest (2014) 0.83
Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins. J Clin Microbiol (2006) 0.83
Memory and naive-like regulatory CD4+ T cells expand during HIV-2 infection in direct association with CD4+ T-cell depletion irrespectively of viremia. AIDS (2011) 0.82
Foxp3 induction in human and murine thymus precedes the CD4+ CD8+ stage but requires early T-cell receptor expression. Immunol Cell Biol (2010) 0.82
Efficient thymopoiesis contributes to the maintenance of peripheral CD4 T cells during chronic human immunodeficiency virus type 2 infection. J Virol (2007) 0.81
Mutations selected in HIV-2-infected patients failing a regimen including atazanavir. J Antimicrob Chemother (2012) 0.81
Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. AIDS (2008) 0.81
CD4⁺ recent thymic emigrants are infected by HIV in vivo, implication for pathogenesis. AIDS (2011) 0.79
Repairing thymic function. Curr Opin Organ Transplant (2013) 0.79
Monocyte and myeloid dendritic cell activation occurs throughout HIV type 2 infection, an attenuated form of HIV disease. J Infect Dis (2013) 0.79
Preserved CD4 T-cell telomere length during long-lasting HIV-2 infection. AIDS (2013) 0.78
Long-term immune reconstitution of naive and memory t cell pools after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2013) 0.78
Gut disruption in HIV-2 infection despite reduced viremia. AIDS (2014) 0.78
Dendritic cell differentiation and maturation in the presence of HIV type 2 envelope. AIDS Res Hum Retroviruses (2009) 0.78
Strategies to quantify unspliced and multiply spliced mRNA expression in HIV-2 infection. J Virol Methods (2011) 0.78
Potential impact of viral load and genetic makeup of HIV type 1 on mother-to-child transmission: characterization of env-C2V3C3 and nef sequences. AIDS Res Hum Retroviruses (2009) 0.77
Increased frequency of CD25dimCD4+ T-cells in HIV-2 infection, a naturally occurring attenuated form of HIV-1. Clin Immunol (2008) 0.77
Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease. Clin Immunol (2007) 0.76
Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia. AIDS (2012) 0.76
Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response. Retrovirology (2013) 0.76